GlassScriptPhysician profile
Naima Maqsood
NPI 1073174744
$7,356.80
in general payments reported to CMS, 2019-2025
17 companies · $5,927 in 2025
The $5,927 reported for 2025 was more than what 98% of Internal Medicine providers received nationally (typical 2025 total: $156).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2022: $77.75 · 2023: $556 · 2024: $795 · 2025: $5,927.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $3,735 · Travel and Lodging: $3,033 · Education: $511.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $3,735.31 |
| Travel and Lodging | $3,032.69 |
| Education | $511.05 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Boston Scientific Corporation | $5,173.03 | 2025 | General - Therapies, Farapulse |
| Abbott Laboratories | $575.06 | 2023-2024 | Ensite, Assurity, Gallant |
| Medtronic, INC. | $411.54 | 2025 | Aurora Ev-Icd Mri Surescan, Linq II |
| Biosense Webster, INC. | $342.79 | 2023-2025 | Carto 3, Soundstar, Nuvision Ice Catheter |
| Baxter Healthcare | $149.34 | 2024 | Hillrom - Cardiac Ambulatory Monitor |
| Zoll Services LLC (A/K/A Zoll Lifecor Corp) | $120.26 | 2023-2025 | Lifevest |
| Merck Sharp & Dohme LLC | $115.95 | 2023-2025 | Verquvo |
| Abiomed | $104.44 | 2022-2025 | Impella |
| Actelion Pharmaceuticals US, INC. | $92.33 | 2024 | Uptravi |
| Impulse Dynamics (USA) INC. | $70.96 | 2023-2025 | Optimizer, Optimizer |
| Livanova USA, INC. | $58.71 | 2022-2023 | Protekduo |
| Pfizer INC. | $29.78 | 2025 | |
| Kiniksa Pharmaceuticals, LTD. | $29.70 | 2023 | Arcalyst |
| Kiniksa Pharmaceuticals International, Plc | $23.95 | 2024 | Arcalyst |
| Astrazeneca Pharmaceuticals LP | $23.78 | 2025 | Farxiga |
Show all 17 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novo Nordisk INC | $21.66 | 2024 | Wegovy |
| Terumo Medical Corporation | $13.52 | 2022 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Naima Maqsood listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.